MANILA, Philippines (UPDATED) – The United Nations (UN) recently launched a collaboration with world leaders and the private sector to “accelerate the development, production, and equitable distribution of vaccines, diagnostics, and therapeutics” for COVID-19.
The launch came after the World Health Organization (WHO) warned that the world still has a “long way to go” in the fight against the coronavirus pandemic. The UN also said a COVID-19 vaccine may be the only thing that can bring back “normalcy” to the world.
According to a May 5 draft landscape document prepared by the WHO*, there are currently at least 8 candidate vaccines in clinical evaluation and 100 candidate vaccines in preclinical evaluation.
WHO’s latest document showed a fourth vaccine by the Beijing Institute of Biological Products/Sinopharm, which according to a The New York Times report is already in Phase 1 trials.
Nasdaq-listed Sinovac Biotech, which developed one of the two vaccines approved for early-stage human trials in April, said its vaccine has for the first time “largely protected” monkeys from coronavirus infection during an animal trial. The Chinese biotech firm published its findings online 3 days after it began human trials, but these findings have yet to be peer reviewed.
In the United States – now the country worst hit by the coronavirus – Inovio Pharmaceuticals announced early April that its vaccine is entering clinical trials.
The vaccine funded by the Coalition for Epidemic Preparedness and the Bill and Melinda Gates Foundation is the second in the US to enter the human testing phase, following Moderna Therapeutics’ candidate vaccine which entered human trials in March.
The University of Oxford, another developer listed in the WHO document, began clinical trials for its coronavirus vaccine in April. The British government reportedly announced a £20-million ($24.7-million) funding to support the university’s trials. Britain is one of the countries worst hit by the coronavirus in Europe.
Germany’s Paul-Ehrlich-Institut approved clinical trials for an RNA vaccine developed by German firm Biontech and US giant Pfizer. According to the WHO document, this vaccine has already entered clinical trials.
Other developers to conduct trials soon
Other vaccine developers also announced their plans to conduct clinical trials soon.
The Harvard University developed a vaccine in collaboration with Janssen Pharmaceutical Companies, the drug-making arm of Johnson & Johnson. It plans to launch clinical trials “in the fall as part of a joint $1-billion collaboration agreement announced by the US government and Johnson & Johnson.” The university is also working on age-specific and subunit vaccines for the virus.
The vaccine is listed in the WHO document under “candidate vaccines in preclinical evaluation,” together with 99 others.
Apart from vaccine development, there is still no specific medicine recommended to prevent or treat COVID-19.
A US government-funded study recently showed that hydroxychloroquine, a malaria drug widely touted as a potential cure, showed no benefit against the disease over standard care. The study has yet to be peer-reviewed.
Meanwhile, results inadvertently released by the WHO showed that the experimental coronavirus treatment remdesivir failed in its first randomized clinical trial. But in May, Japan authorized remdesivir to treat coronavirus patients – the second such country to approve the drug after the United States.
Japan is also aiming to approve antiviral drug Avigan this May.
Some countries have already started easing lockdown restrictions amid the pandemic that has so far infected over 2.8 million people and killed over 200,000 across 193 countries and territories. – Jee Y. Geronimo, with reports from Agence France-Presse/Rappler.com
More stories on potential cures and vaccines for the coronavirus:
- Coronavirus drugs: Who’s doing what, and when they might come
- What you need to know: Coronavirus cures, vaccines being tested
*The WHO prepared the document for information purposes only. According to the WHO, a product or entity’s inclusion in any of these landscape documents “does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity.”